Product Details

Chasing Away Phantom Investigators

The incidence of investigator absence from supervising clinical trials is growing as more trials are being conducted, more professionals are speaking out and sponsors, CROs and regulatory agencies tracking it more actively. To address this problem, FDA and industry are taking steps to implement new processes, to train and educate clinical investigators, and to require more accountability from investigative sites.

The Dismantling of ICSL

Once an SMO market leader, ICSL exits the business due to a complex combination of financial, legal, operational and political problems. In its wake, ICSL leaves behind hundreds of millions of dollars in losses, disappointed investigative sites and investors. Comprehensive Neurosciences is expected to buy what remains of the ICSL site network.

Also in this issue:

• CentreStage Europe: WIRB Finds European Market Tough Sledding
• Eye On: Lung Cancer